PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (SG11201806282X) HIGH-THROUGHPUT IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES

Office : Singapore
Application Number: 11201806282X Application Date: 10.02.2017
Publication Number: 11201806282X Publication Date: 30.08.2018
Publication Kind : A1
Prior PCT appl.: Application Number:PCTUS2017017549 ; Publication Number:2017139694 Click to see the data
IPC:
G06F 19/18
C12Q 1/68
G01N 33/569
G01N 33/574
A61K 35/17
A61K 39/00
A61K 39/395
A61K 47/50
A61K 48/00
G PHYSICS
06
COMPUTING; CALCULATING; COUNTING
F
ELECTRIC DIGITAL DATA PROCESSING
19
Digital computing or data processing equipment or methods, specially adapted for specific applications
10
Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
18
for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
569
for micro-organisms, e.g. protozoa, bacteria, viruses
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
[IPC code unknown for A61K 35/17]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
[IPC code unknown for A61K 47/50]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applicants: NANTOMICS, LLC
NANT HOLDINGS IP, LLC
Inventors: NGUYEN, Andrew
SANBORN, John, Zachary
BENZ, Stephen, Charles
NIAZI, Kayvan
RABIZADEH, Shahrooz
SOON-SHIONG, Patrick
VASKE, Charles, Joseph
Priority Data: 62/294,665 12.02.2016 US
Title: (EN) HIGH-THROUGHPUT IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES
Abstract:
(EN) 250000 200000 6 150000 100000 50000 0 Detection: DNA RNA netMHC A'02:01 Restricted Samples Necepitopes EUCEC (14) ! THCA (10) 1STAD (1) _j READ (4) OPRAD (10) LUSC (15) LUAD (17) Ej KIRC (13) DHNSC (25) 3COAD (3) BRCA (28) BLCA (3) Cancer Gene Classification of Neoepitopes Non-Cancer Genes 1:1 Cancer Driving Genes 94% FIG. 2 W O 20 17 / 13969 4 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/139694 Al 17 August 2017 (17.08.2017) WIPO I PCT 111111111111110111011111111111010111110 0111011111011111111101111111111111110111111 (51) International Patent Classification: GOOF 19/18 (2011.01) A61K 39/00 (2006.01) C12Q 1/68 (2006.01) A61K 39/395 (2006.01) GO1N 33/569 (2006.01) A61K 47/50 (2017.01) GO1N 33/574 (2006.01) A61K 48/00 (2006.01) A61K 35/17 (2014.01) (21) International Application Number: PCT/US2017/017549 (22) International Filing Date: 10 February 2017 (10.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/294,665 12 February 2016 (12.02.2016) US (71) Applicants: NANTOMICS, LLC [US/US]; 9920 Jeffer- son Boulevard, Culver City, CA 90232 (US). NANT HOLDINGS IP, LLC [US/US]; 9920 Jefferson Boulevard, Culver City, CA 90232 (US). = (72) Inventors: NGUYEN, Andrew; 9920 Jefferson Boulevard, Culver City, CA 90232 (US). SANBORN, John, Zachary; 9920 Jefferson Boulevard, Culver City, CA 90232 (US). BENZ, Stephen, Charles; 436 Park Way, Santa Cruz, CA 95062 (US). NIAZI, Kayvan; 9920 Jeffer- son Boulevard, Culver City, CA 90232 (US). RABIZA- DEH, Shahrooz; 9920 Jefferson Boulevard, Culver City, CA 90232 (US). SOON-SHIONG, Patrick; 9920 Jeffer- son Boulevard, Culver City, CA 90232 (US). VASKE, Charles, Joseph; 9920 Jefferson Boulevard, Culver City, CA 90232 (US). (74) Agents: FESSENMAIER, Martin et al.; Fish & Tsang, LLP, 2603 Main Street, Suite 1000, Irvine, CA 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, [Continued on next page] (54) Title: HIGH-THROUGHPUT IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES (57) Abstract: Systems and methods are presented that allow for selection of tumor neoepitopes that are filtered for various criteria. In particularly contemplated aspects, filtering includes a step in which the mutation lead- ing to the neoepitope is ascertained as being located in a cancer driver gene. WO 2017/139694 Al MIDEDIMOMOIDEIR010130111001MOIMOIMMEHOIMI TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with amended claims (Art. 19(1))
Also published as:
AU2017217877CA3014252KR1020180091119CN108701172IL261090EP3414692
US20190034582WO/2017/139694